Last edition
News about "FTC tracks pharma strategies as patent cliff appro"
FTC Tracks Pharma Strategies as Patent Cliff Approaches
The US Federal Trade Commission (FTC) is keeping a close watch on how pharmaceutical companies respond as several blockbuster drugs approach the end of their patent life. The regulator is particularly concerned about practices that could delay the entry of lower-cost generic medicines.
FTC Tracks Pharma Strategies As Patent Cliff Appro | 18/03/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members